Rarebase’s Bold Strategy: Repurposing Drugs for the Rare Disease Frontier

The landscape of drug discovery is undergoing a radical shift as specialized laboratories move away from the traditional blockbuster drug model toward highly personalized, data-driven interventions for rare diseases. At the center of this movement is Rarebase, a public benefit corporation that has gained significant attention for its proprietary Function platform. This technology is designed to address a staggering medical void: while millions of people globally suffer from one of the approximately 10,000 known rare diseases, the vast majority of these conditions—roughly 95%—lack any FDA-approved treatment. The traditional pharmaceutical industry often finds these markets too small to justify the multi-billion dollar investment required for ground-up drug development, leaving families to fend for themselves.

Rarebase’s approach is fundamentally different from the industry standard. Rather than spending a decade developing a single new molecule, the lab utilizes high-throughput screening to test thousands of existing, FDA-approved drugs against the genetic profiles of patients with rare disorders. By measuring changes in gene expression—a field known as transcriptomics—the lab can identify if an existing medication for a common condition might inadvertently fix the expression of a mutated gene responsible for a rare neurological or metabolic disorder. This strategy of drug repurposing significantly collapses the timeline and cost of bringing relief to patients, as the safety profiles of these drugs are already well-documented and they are already available in pharmacies.

“

This technology is designed to address a staggering medical void: while millions of people globally suffer from one of the approximately 10,000 known rare diseases, the vast majority of these conditions—roughly 95%—lack any FDA-approved treatment.

The business model supporting this research is as innovative as the science itself. Rarebase operates as a Public Benefit Corporation (PBC), a structure that allows it to balance fiduciary duties to shareholders with a mission-driven commitment to patient outcomes. A key component of their strategy involves direct collaboration with patient advocacy groups. These organizations, often founded by parents of children with ultra-rare conditions, provide the funding and biological samples necessary for the research. In return, they gain access to a professional-grade drug discovery engine that was previously only available to the world’s largest pharmaceutical companies. This democratization of biotechnology is creating a new ecosystem where patients are no longer passive recipients of care but active partners in the research process.